INTRODUCTION
The incidence of gastric carcinoids, here collectively termed neuroendocrine (NE)b tumors of the stomach [1] , was thought to be low [2, 3] , not exceeding three percent of all gastrointestinal neuroendocrine tumors. Recent reports, however, have challenged this figure and suggested that the true incidence of gastric neuroendocrine tumors (GNET) ranges between 11 percent and 41 percent [4] [5] [6] . These rising figures probably do not represent a true increase in incidence, but rather indicate that the rate of occurrence was underestimated in former times, because the small GNETs associated with chronic atrophic corpus gastritis (CAG) were scarcely detected in the pre-endoscopic era.
The fact that GNETs are quite frequently encountered by the active endoscopist raises the question as to their biology and clinical significance. During recent years, the available information has increased rapidly, culminating in detailed accounts that have led to a better understanding of these lesions. As a consequence, new classifications that take their biology and prognosis into account have been developed [1, [7] [8] [9] . Based on this work, GNETs can be divided into four types, which we shall describe in more detail below. CLASSIFICATION Type 1 gastric neuroendocrine tumors Type 1 GNET is the most frequent neuroendocrine tumor in the stomach, with a relative incidence between 51 percent and 88 percent [8, 10] (Table 1 ). This tumor is associated with aTo whom all correspondence should be addressed: Prof. G. Kloppel [10] . If only patients with pernicious anemia are considered, GNETs may be found in five to 10 percent of the patients [4, 11] . Because of the disappearance of HCl-producing cells in the fundic mucosa of the stomach, there is sustained hypergastrinemia. Gastrin, however, is trophic for the ECL cells of the fundic mucosa [12] [13] [14] [15] [16] , leading to their numerical increase (hyperplasia) and promoting their eventual clonal proliferation (tumor). Tumor development is usually multicentric and very slow, resulting in multiple small tumors (< 1 cm), which are restricted to the mucosa and submucosa. Tumors that are larger than 1 cm and invade vessels and/or the muscular wall of the stomach are extremely rare. Metastasis to the regional lymph nodes or liver is therefore the exception [8, 10] . This implies that type 1 GNET can be controlled by endoscopic surgery and have an excellent prognosis. Interestingly, regression of ECL-cell gastric carcinoids has been reported in patients with pernicious anemia after elimination of hypergastrinemia by antrectomy [17] . The [8] . Patients in whom metastasis has occurred have a mean survival of about four years. Histologically, the tumors usually show a trabecular pattern, and immunocytochemically they stain for neuroendocrine markers [8, 10] and for biogenic amines and peptides such as serotonin, histamine, glucagon, pancreatic polypeptide and others [19, 20] . Serotonin or histaminepositive tumors with metastasis to the liver (about 20 to 25 percent of all type 2 gastric NE tumors) produce either a classical carcinoid syndrome (due to the systemic effects of serotonin) or an atypical carcinoid syndrome (due to the effects of histamine [21, 22] ).
Among the sporadic GNETs, there are a few that produce gastrin. A survey of the literature revealed eight of these tumors that were immunocytochemically verified and another seven tumors without detailed morphologic description (Table 3 ). These gastric gastrinomas may be differentiated from the remaining GNETs, not only because of their gastrin production, but also because of their peculiar localization. All but three of the immunocytochemically identified gastrin-producing GNETs arose in the antropyloric region. Type 3 gastric neuroendocrine tumors Type 3 GNETs are those that arise against the background of the inherited syndrome of multiple endocrine neoplasia type 1 (MEN-1) presenting with the Zollinger-Ellison syndrome (ZES) ( Table 4) . In this condition, the gastrinoma responsible for the ZES and hypergastrinemia is usually found in the duodenum [33, 34] . In addition to hypertrophic gastropathy, hypergastrinemia causes ECL cell hyperplasia in the oxyntic mucosa. ECL tumors may also occur in addition to ECL cell hyperplasia, but the tumors are thought to be promoted by the genetic changes underlying MEN-I since similar tumors have never been observed in association with sporadic ZES [8] , apart from one doubtful case [35] . The MEN-1/ZES associated tumors are usually small (mean 0.5 cm; range 0.1-1.6 cm) but may occasionally become large [36] or involve the oxyntic mucosa diffusely [37] . Metastasis to the regional lymph nodes has been observed in a few tumors [8, 36] , all of them large. Type 4 gastric neuroendocrine tumors This GNET is characterized by its poor differentiation (Table 5) . Histologically, the tumor is composed of medium-sized, rather than small cells, showing high proliferation activity. At the time of diagnosis, most of the tumors are already advanced. Their prognosis is therefore poor, with three quarters of the patients dying within one year of diagnosis due to extensive metastatic disease [8, 10, [38] [39] [40] [41] [42] . CONCLUSION The GNETs show a broad functional and biological spectrum, which makes a division into different types necessary. The classification outlined in this paper considers the morphology and function of the tumors and their association with other diseases. On this basis four types can be distinguished, each with its own clinical relevance.
